Business
ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS
Based in New Jersey (USA), to lead ORYZON’s CNS clinical development MADRID and CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer, CNS Programs. Dr. Gutierrez-Esteinou is a Harvard-trained psychiatrist and an accomplished global clinical development executive with more tha
About this update from Oryzon Genomics Sa
[{"type":"image","alt":"Oryzon Genomics, S.A.","displaySize":"","headline":null,"caption":"Oryzon Genomics, S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":182,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cNdaqSWVXmpOQnfrePXGFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEzODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2","width":182,"height":70}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Based in New Jersey (USA), to lead ORYZON’s CNS clinical development","length":68,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":68,"olType":false},{"type":"text","content":"MADRID and CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer, CNS Programs. Dr. Gutierrez-Esteinou is a Harvard-trained psychiatrist and an accomplished global clinical development executive with more than 20 years of leadership experience advancing neuroscience and psychiatry-focused drug development programs. He brings deep expertise in late-stage clinical execution, regulatory strategy, and pathways to market approval.","length":652,"tagName":"p"},{"type":"text","content":"“Rolando is an outstanding addition to Oryzon’s executive team,” said Carlos Buesa, Chief Executive Officer of Oryzon. “He brings a rare combination of deep clinical expertise in psychiatry, extensive late-stage CNS development experience, and proven regulatory leadership. His strong track record in advancing innovative therapies through pivotal development and supporting successful regulatory submissions will be invaluable as we prepare to move vafidemstat, our lead CNS program, into Phase III clinical development for the treatment of agitation and aggression (A/A) in borderline personality disorder (BPD), while also expanding its clinical development in A/A in autism spectrum disorder and in negative symptoms of schizophrenia, with a clear path toward future regulatory approval.”","length":792,"tagName":"p"},{"type":"text","content":"Most recently, Dr. Gutierrez-Esteinou served as Chief Medical...